Pharmacotherapy of Neuropsychiatric Syndromes in Neurologic Disorders: Definitional and Regulatory Aspects

Name: Pharmacotherapy of Neuropsychiatric Syndromes in Neurologic Disorders: Definitional and Regulatory Aspects
SKU: 2835
Price: 30.00 USD
Availability: InStock

$30.00

Pharmacotherapy of Neuropsychiatric Syndromes in Neurologic Disorders: Definitional and Regulatory Aspects

Jeffrey L. Cummings, MD and Dilip V. Jeste, MD

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 40 No. 4 Articles Tags: alzheimers, dilip-v-jeste, fda, jeffrey-l-cummings, labeling, neuropsychiatric, nimh, pharmacotherapy, pharmacotherapy-of-neuropsychiatric-syndromes, pseudospecificity

Description

Description

Pharmacotherapy of Neuropsychiatric Syndromes in Neurologic Disorders: Definitional and Regulatory Aspects

Jeffrey L. Cummings, MD and Dilip V. Jeste, MD

PB-40-4-06-CUMMINGS

Pharmacotherapy of Neuropsychiatric Syndromes in Neurologic Disorders: Definitional and Regulatory Aspects

Description

Alzheimer’s and Dementia Guidelines and Tables

Psychopharmacology Bulletin VOL 49 No. 1, 2019 – Full Issue Stacked PDF

Adjunctive Pimavanserin in Patients with Major Depressive Disorder: Combined Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies

Strategies for Treatment-Resistant Depression

Pharmacotherapy of Neuropsychiatric Syndromes in Neurologic Disorders: Definitional and Regulatory Aspects

Description

Related products

Alzheimer’s and Dementia Guidelines and Tables

Psychopharmacology Bulletin VOL 49 No. 1, 2019 – Full Issue Stacked PDF

Adjunctive Pimavanserin in Patients with Major Depressive Disorder: Combined Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies

Strategies for Treatment-Resistant Depression